Townsend Letter Report Follows International Interest in Oxaloacetate As Missing Link in Chronic Fatigue and Long COVID
Aktie
Interest continues to grow in the scientific and medical communities for the potential of oxaloacetate medical food to provide relief for the millions struggling with ME/CFS and Long COVID.
Following highlights of Oxaloacetate CFS clinical trial results at the two leading international ME/CFS conferences (IACFS/ME 2025 and the 2025 International Chronic Fatigue Syndrome Conference) the longstanding medical journalism pillar Townsend Letter has published the feature, “Oxaloacetate: A Missing Link in CFS, Long-Haul COVID, and Mitochondrial Performance.”
Spotlight in Townsend Letter
In Townsend Letter’s latest issue, Dr. Chris Meletis provides the clinical evidence that support Oxaloacetate CFS as an effective, targeted intervention for the cellular dysfunction underlying chronic fatigue.
Meletis explains how oxaloacetate is involved in critical cellular energy pathways and offers hope for patients whose energy production has been compromised. Referencing recent clinical trials, the report explains the disruptions in mitochondrial efficiency that translate into overwhelming fatigue, brain fog, and post-exertional malaise. Townsend Letter presents data that show replenishing oxaloacetate, a key metabolic stage in the Kreb’s cycle, with Oxaloacetate CFS can support reduction in both mental and physical fatigue in ME/CFS and Long COVID patients.
Clinical Evidence
Several clinical trials have evaluated Oxaloacetate CFS in ME/CFS and Long COVID populations showing:
-
Fatigue reduction: Studies have reported up to a 25–35% improvement in fatigue after just three months of daily use.
-
Enhanced response rates: Over 40% of patients have been classified as “enhanced responders,” experiencing an average 63% reduction in fatigue.
- Cognitive improvements: Beyond physical energy, oxaloacetate has also demonstrated statistically significant benefits in mental clarity and overall symptom burden.